{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:20:45Z","timestamp":1777904445259,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xops.2026.101126","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:03:11Z","timestamp":1771866191000},"page":"101126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Evaluation of Safety and Efficacy of QLS-111: A Novel Formulation of an Adenosine Triphosphate-Sensitive Potassium Channel Opener"],"prefix":"10.1016","volume":"6","author":[{"given":"Barbara M.","family":"Wirostko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uttio","family":"Roy Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Brandano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph A.","family":"Casale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"DeWalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura R.","family":"Rykard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thurein M.","family":"Htoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Fautsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101126_bib1","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101126_bib2","article-title":"Epidemiology of glaucoma: the past, present, and predictions for the future","volume":"12","author":"Allison","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.xops.2026.101126_bib3","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/archopht.1977.04450080088009","article-title":"Carbonic anhydrase inhibitor side effects. Serum chemical analysis","volume":"95","author":"Epstein","year":"1977","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101126_bib4","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/archopht.1981.03930020845006","article-title":"The influence of supplemental sodium acetate on carbonic anhydrase inhibitor-induced side effects","volume":"99","author":"Arrigg","year":"1981","journal-title":"Arch Ophthalmol"},{"issue":"Pt 3","key":"10.1016\/j.xops.2026.101126_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/eye.1995.79","article-title":"Prevalence of chronic hypokalaemia amongst elderly patients using acetozolamide and diuretics","volume":"9","author":"Davis","year":"1995","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2026.101126_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/mja2.50020","article-title":"Current management of glaucoma","volume":"210","author":"Lusthaus","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.xops.2026.101126_bib7","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bjophthalmol-2021-319530","article-title":"Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?","volume":"106","author":"Stoner","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101126_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajo.2023.05.007","article-title":"Risks of topical carbonic anhydrase inhibitors in glaucoma patients with chronic kidney disease: a nationwide population-based study","volume":"253","author":"Wang","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101126_bib9","article-title":"Bradycardia from a non-selective beta-adrenergic antagonist, timolol, applied ophthalmologically for glaucoma","volume":"14","author":"May","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.xops.2026.101126_bib10","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101126_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/108076802760116205","article-title":"A retrospective review of non-responders to latanoprost","volume":"18","author":"Scherer","year":"2002","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101126_bib12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.preteyeres.2016.12.004","article-title":"Aqueous outflow - a continuum from trabecular meshwork to episcleral veins","volume":"57","author":"Carreon","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2026.101126_bib13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/archopht.1963.00960040789022","article-title":"Experimental aqueous perfusion in enucleated human eyes","volume":"69","author":"Grant","year":"1963","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101126_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.exer.2008.11.033","article-title":"The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium","volume":"88","author":"Overby","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2026.101126_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000088378","article-title":"Episcleral venous pressure in untreated primary open-angle and normal-tension glaucoma","volume":"219","author":"Selbach","year":"2005","journal-title":"Ophthalmologica"},{"issue":"5","key":"10.1016\/j.xops.2026.101126_bib16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/jop.2017.0138","article-title":"The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans","volume":"34","author":"Kazemi","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101126_bib17","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.1167\/iovs.11-7523","article-title":"ATP-sensitive potassium (KATP) channel activation decreases intraocular pressure in the anterior chamber of the eye","volume":"52","author":"Chowdhury","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101126_bib18","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1167\/iovs.13-11872","article-title":"ATP-Sensitive potassium (KATP) channel openers diazoxide and nicorandil lower intraocular pressure in vivo","volume":"54","author":"Chowdhury","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101126_bib19","article-title":"Correction: ocular hypotensive effects of the ATP-sensitive potassium channel opener cromakalim in human and murine experimental model systems","volume":"10","author":"Roy Chowdhury","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101126_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179345","article-title":"ATP-sensitive potassium (KATP) channel openers diazoxide and nicorandil lower intraocular pressure by activating the Erk1\/2 signaling pathway","volume":"12","author":"Roy Chowdhury","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101126_bib21","article-title":"Pharmacologic profile and distribution of CKLP1, a novel prodrug of the ATP-sensitive potassium channel opener cromakalim, following various modes of administration","volume":"58","author":"Roy Chowdhury","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101126_bib22","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1167\/iovs.17-22538","article-title":"Effect of cromakalim prodrug 1 (CKLP1) on aqueous humor dynamics and feasibility of combination therapy with existing ocular hypotensive agents","volume":"58","author":"Roy Chowdhury","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101126_bib23","first-page":"201","article-title":"Modulation of Intraocular pressure by ATP sensitive potassium channel openers","volume":"2","author":"Roy Chowdhury","year":"2018"},{"key":"10.1016\/j.xops.2026.101126_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231841","article-title":"Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits","volume":"15","author":"Roy Chowdhury","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101126_bib25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/jop.2020.0137","article-title":"Pharmacological profile and ocular hypotensive effects of cromakalim prodrug 1, a novel ATP-sensitive potassium channel opener, in normotensive dogs and nonhuman Primates","volume":"37","author":"Roy Chowdhury","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101126_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/iovs.63.2.15","article-title":"Effect of ATP-sensitive potassium channel openers on intraocular pressure in ocular hypertensive animal models","volume":"63","author":"Roy Chowdhury","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101126_bib27","article-title":"Ocular hypotensive effects of the ATP-sensitive potassium channel opener cromakalim in human and murine experimental model systems","volume":"10","author":"Roy Chowdhury","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101126_bib28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1167\/iovs.10-6069","article-title":"Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion. Research support, non-U.S. gov't","volume":"52","author":"Millar","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101126_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.exer.2015.04.018","article-title":"Non-continuous measurement of intraocular pressure in laboratory animals","volume":"141","author":"Millar","year":"2015","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2026.101126_bib30","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1167\/iovs.15-16720","article-title":"Strain and age effects on aqueous humor dynamics in the mouse","volume":"56","author":"Millar","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101126_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.63.4.26","article-title":"Ocular hypotensive properties and biochemical profile of QLS-101, a novel ATP-sensitive potassium (KATP) channel opening prodrug","volume":"63","author":"Pervan-Steel","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101126_bib32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/jop.2022.0184","article-title":"Preclinical pharmacokinetic profile of topical ophthalmic and intravenous delivery of QLS-101, a novel ATP-sensitive potassium channel opening ocular hypotensive agent","volume":"39","author":"Roy Chowdhury","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101126_bib33","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1021\/acs.jmedchem.6b00406","article-title":"Analogs of the ATP-sensitive potassium (KATP) channel opener cromakalim with in vivo ocular hypotensive activity","volume":"59","author":"Roy Chowdhury","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.xops.2026.101126_bib34","article-title":"Elevated intraocular pressure due to arteriovenous fistula between external carotid artery and facial vein","volume":"2014","author":"Cagatay","year":"2014","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.xops.2026.101126_bib35","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IJG.0000000000001307","article-title":"Episcleral venous pressure and the ocular hypotensive effects of topical and intracameral prostaglandin analogs","volume":"28","author":"Lee","year":"2019","journal-title":"J Glaucoma"},{"key":"10.1016\/j.xops.2026.101126_bib36","first-page":"871","article-title":"Ocular manifestations of Sturge-Weber syndrome: pathogenesis, diagnosis, and management","volume":"10","author":"Mantelli","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101126_bib37","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1001\/archopht.1978.03910060433007","article-title":"The mechanism of timolol in lowering intraocular pressure","volume":"96","author":"Coakes","year":"1978","journal-title":"Normal Eye Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101126_bib38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/IJG.0b013e3181d12dd8","article-title":"Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment","volume":"19","author":"Johnson","year":"2010","journal-title":"J Glaucoma"},{"key":"10.1016\/j.xops.2026.101126_bib39","series-title":"AHRQ Comparative Effectiveness Reviews","article-title":"Treatment for glaucoma: comparative effectiveness","author":"Boland","year":"2012"},{"key":"10.1016\/j.xops.2026.101126_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-158-4-201302190-00008","article-title":"Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Research Support, U.S. Gov't, P.H.S. Review","volume":"158","author":"Boland","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.xops.2026.101126_bib41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ajhp\/62.7.691","article-title":"Glaucoma and its treatment: a review","volume":"62","author":"Lee","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.xops.2026.101126_bib42","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Clinical trial randomized controlled trial research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101126_bib43","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ajo.2011.06.004","article-title":"An assessment of the health and economic burdens of glaucoma. Research Support, Non-U.S. Gov't Review","volume":"152","author":"Varma","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101126_bib44","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","article-title":"Primary open-angle glaucoma. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review","volume":"363","author":"Weinreb","year":"2004","journal-title":"Lancet"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:25:05Z","timestamp":1777638305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666914526000643"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101126","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Evaluation of Safety and Efficacy of QLS-111: A Novel Formulation of an Adenosine Triphosphate-Sensitive Potassium Channel Opener","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101126"}}